| 8:30-9:45 Session 3: Biology of breast cancer II: Tumor heterogeneity and disease segmentation in breast cancer |
| 议程3：乳腺癌生物学II：乳腺癌的肿瘤异质性和疾病划分 |
| 主持：Fraser W. Symmans，Jonas Bergh |
| Intratumor heterogeneity: Targeting multiple trunk and branch drivers in breast cancer |
讲者：Charles Swanton |
| 肿瘤内异质性：靶向于乳腺癌的多个主要和次要驱动因素 |
| Heterogeneity of Triple Negative subtype: Gene expression profile and phenotype |
讲者：Brian D. Lehmann |
| 三阴性乳腺癌的异质性:基因表达谱和表型 |
| Molecular segmentation in Luminal breast cancer: How to select the driver pathways |
讲者：Sherene Loi |
| luminal型乳腺癌的分子分类：如何选择驱动通路 |
| Insights in biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications |
讲者：Nadja Harbeck |
| 思考luminal HER-2与富集HER-2亚型之间的生物学特征：对治疗的启示 |
| 讨论 |
|
| 9:45-10:45 Session 4: Biology of breast cancer III: Genome remodeling and tumor microenvironment |
| 议程4：乳腺癌生物学III：基因组重构和肿瘤微环境 |
| 主持：Mitch Dowsett，Daniel F. Hayes |
| Tumor-stroma crosstalk: Targeting stroma and inflammation |
讲者：Frances Balkwill |
| 肿瘤与基质的相互作用：靶向于基质和炎症 |
| Immune-pathways and immunome as a target |
讲者：Giuseppe Curigliano |
| 可作为目标的免疫通路和免疫组 |
| Targeting bone microenvironment: Clinical implications |
讲者：Michael Gnant |
| 靶向于骨微环境：临床启示 |
| 讨论 |
|
| 11:20-12:30 Session 5: Bridging clinic with biology: Emerging drugable pathways on the horizon |
| 议程5：链接临床和生物学：药物开发即将成功的通路 |
| 主持：Giuseppe Curigliano，Clifford Hudis |
| Targeting CDK 4-6 pathway |
讲者：Richard S. Finn |
| 靶向CDK4-6通路 |
| Targeting DNA repair pathways |
讲者：Andrew Tutt |
| 靶向DNA修复通路 |
| Targeting PIK3CA pathway |
讲者：José Baselga |
| 靶向PIK3CA通路 |
| Targeting FGFR pathway |
讲者：Nicholas Turner |
| 靶向FGFR通路 |
| 讨论 |
|
| 14:00-15:00 Session 6: Primary prevention， metabolism and genetics |
| 议程6：一级预防，代谢和遗传学 |
| 主持：John F. Forbes，Marco Colleoni |
| Using germline genetics in the management of breast cancer patients and their families |
讲者：Judy Garber |
| 利用生殖细胞遗传学管理乳腺癌患者及其亲属 |
| Preventing invasive breast cancer in women at high risk based on benign/in situ pathology |
讲者：Jack Cuzick |
| 基于良性或原位病变预防高危女性侵袭性乳腺癌的发生 |
| Obesity and insulin resistance: Correlations and time course of prognostic associations |
讲者：Pamela J. Goodwin |
| 肥胖和胰岛素抵抗：与预测作用的关系和时间进程 |
| 讨论 |
|
| 15:00-16:15 Session 7: Beyond pathology of breast cancer in 2015 |
| 议程7：乳腺癌病理学在2015年的新拓展 |
| 主持：Giuseppe Viale; Hervé Bonnefoi |
| The special case of “equivocal” pathological biomarkers (ER， PgR and HER2): Implications for breast cancer treatment |
讲者：Fraser W. Symmans |
| 病理学标志物模棱两可的特殊案例（ER，PgR和HER-2）：对乳腺癌治疗的启示 |
| BCL-2: A new therapeutic target in estrogen receptor-positive breast cancer? |
讲者：Geoffrey J. Lindeman |
| BCL-2：雌激素受体阳性乳腺癌的新治疗靶点？ |
| The changing role of ER in endocrine resistance |
讲者：C. Kent Osborne |
| ER在内分泌耐药中的角色转变 |
| Developing Ki-67 as a useful marker |
讲者：Carsten Denkert |
| 将Ki-67开发成为有用标志物 |
| 讨论 |
|
| 16:45-18:00 Session 8: Primary systemic therapy of early breast cancer |
| 议程8：早期乳腺癌的一线全身治疗 |
| 主持：Eric Winer; Giuseppe Curigliano |
| Primary systemic therapy for clinicians: Medical and research perspectives |
讲者：Sybille Loibl |
| 临床医生从医疗和研究角度看待一线全身治疗 |
| Clinical usefulness and relevance of intermediate endpoints for cytotoxic primary systemic therapy |
讲者：Gunter von Minckwitz |
| 细胞毒性一线全身治疗的中期终点临床应用和意义 |
| Clinical trial designs in the neoadjuvant setting: Challenges of the genomic era |
讲者：Lisa Carey |
| 新辅助治疗的临床试验设计：来自基因组时代的挑战 |
| 讨论 |
|
京公网安备 11010502033352号